Medical Injectable Drug Crysvita to Require Prior Authorization
Thu, May 14, 2026
Effective on the dates below, the medical injectable drug Crysvita will require prior authorization for all lines of business:
- July 15, 2026 – Delaware, Pennsylvania, and West Virginia
- Aug. 15, 2026 – New York
Applicable Procedure Code Details
|
Procedure Code |
Generic |
Brand |
|---|---|---|
|
J0584 |
burosumab-twza |
Crysvita |
Plan-preferred product and Site of Care considerations may apply in line with member benefits. Please confirm the most up-to-date coverage criteria outlined in Highmark’s applicable medical policies, which can be searched via the links available on the Medical Policies page of the Provider Resource Center (PRC).
Our List of Procedures and Durable Medical Equipment (DME) Requiring Authorization is subject to change. To view the current list for your region, go to the PRC's Obtaining Authorizations page.
Quick Info
Never miss out on what matters. Subscribe to our emails and stay informed.
